Author: Richard Holdcroft

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

Alaskan high grade gold and antimony explorer aiming for near term, high-grade antimony production.

High-grade greener iron ore developer in its final stages before significant potential value creation.

Disrupting a $300bn industry which has not seen innovation in decades

High-grade greener iron ore developer in its final stages before significant potential value creation.

High-grade greener iron ore developer in its final stages before significant potential value creation.

Large-scale, development-ready, copper project with the potential to become a top-10 US producer.

High-grade greener iron ore developer in its final stages before significant potential value creation.

High-grade greener iron ore developer in its final stages before significant potential value creation.

High-grade greener iron ore developer in its final stages before significant potential value creation.

High-grade greener iron ore developer in its final stages before significant potential value creation.

One of the most advanced cancer therapies on the ASX, Prescient Therapeutics’ (ASX: PTX) PTX-100 is a first-in-class technology which has seen the cancer halt or reduce in 100% of assessable CTCL patients and zero drug related serious adverse events....

Advanced Energy Minerals (ASX: AEM) is the only ASX-listed commercial-scale High Purity Alumina (HPA) producer and one of the only companies globally able to produce ultra-low alpha HPA at commercial scale - a critical material used in advanced AI chips. China controls...

Having moved to Silicon Valley, Australian big data / AI company Zetaris is at the centre of solving one of the biggest bottlenecks within the most significant shift in our lifetime, targeting a billion dollar plus exit in the next 1-2...

If you’re an Australian investor asking, “Where can I still get a decent cash yield?” – you’re not alone.

Australian big data company Xsights has managed what most tech companies dream of: the potential to sign contracts worth $100s million ARR with companies worth $100s billion, driven mostly by inbound demand.

One in five people will get cancer in their lifetime – almost everyone has been touched by the disease in one way or another.

A potential once-in-a-generation opportunity has opened up for the companies that can deliver the critical metals projects the world needs for the green energy transition.

The global antimony market has undergone a dramatic transformation.

Australian tech company Xsights is set to disrupt the ~$300 billion global pork production market.

Since Trump has taken over, we have seen tariffs, trade wars and a massive spike in market volatility.

People have historically been skeptical of Bitcoin, but recently even the largest financial institutions like BlackRock, JP Morgan and Goldman Sachs have moved into the asset class due to its growth prospects and diversification benefits.

As copper moves up in price and into the headlines, Australian developer Copper Bay is preparing for a 2025 IPO on the ASX.

Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.

Please join Connec Chairman Kim Manley for an investor briefing.

Please join Connec Chairman Kim Manley for an investor briefing.

Please join Connec Chairman Kim Manley for an investor briefing.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.

Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.

Please join Prescient Therapeutics CEO James McDonnell for an investor briefing.

Please join Xsights Co-Founder and CEO Steve Wildisen for an investor briefing.

Please join Connec Chairman Kim Manley for an investor briefing.

Please join Felix Gold Executive Director Joe Webb for an investor briefing.

Please join Wellnex Life Managing Director, Zack Bozinvoski for an investor briefing.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.